{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T22:21:47Z","timestamp":1784154107522,"version":"3.55.0"},"reference-count":31,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000092","name":"U.S. National Library of Medicine","doi-asserted-by":"publisher","award":["T15 NLM007059"],"award-info":[{"award-number":["T15 NLM007059"]}],"id":[{"id":"10.13039\/100000092","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008460","name":"National Center for Complementary and Integrative Health","doi-asserted-by":"publisher","award":["U54 AT008909"],"award-info":[{"award-number":["U54 AT008909"]}],"id":[{"id":"10.13039\/100008460","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Res &amp; Perspec"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Data addressing safety concerns related to potential drug interactions between cannabis\u2010derived products and pharmaceutical medications in the pediatric population are lacking. In this study, we retrieved case reports through a published literature search using PubMed and spontaneous reporting data using the Food and Drug Administration's Adverse Event Reporting System (FAERS) to identify potential cannabis\u2013 and cannabinoid\u2013drug interactions in individuals younger than 18\u2009years old. To evaluate the published case reports, we used the Drug Interaction Probability Scale (DIPS), a 10\u2010item questionnaire designed to discern the causal relationship between a potential drug interaction and adverse drug reactions (ADRs). FAERS reports were deduplicated and analyzed to gather information regarding patient demographics, associated drugs, nature of the ADRs, outcomes, professions of the reporters, and reporting timelines. Seven published case reports and 9142 FAERS ADRs reports were included in the final analysis. Based on the findings, caution is warranted when cannabis or cannabinoids are used in combination with prescribed medications, including methadone, everolimus, fluoxetine, and paroxetine. Cannabinoids may inhibit drug\u2010metabolizing enzymes, including several cytochrome P450s, leading to increased drug exposure and potentially, an increased risk for ADRs.<\/jats:p>","DOI":"10.1002\/prp2.70046","type":"journal-article","created":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T06:39:07Z","timestamp":1735108747000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Part 1: Evaluation of Pediatric Cannabis\u2013Drug Interaction Reports"],"prefix":"10.1002","volume":"13","author":[{"given":"Maryann R.","family":"Chapin","sequence":"first","affiliation":[{"name":"School of Pharmacy, University of Pittsburgh  Pittsburgh Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra L.","family":"Kane\u2010Gill","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Pittsburgh  Pittsburgh Pennsylvania USA"},{"name":"Department of Biomedical Informatics University of Pittsburgh  Pittsburgh Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Li","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Pittsburgh  Pittsburgh Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kojo","family":"Abanyie","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics University of Pittsburgh  Pittsburgh Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanya B.","family":"Taneja","sequence":"additional","affiliation":[{"name":"Intelligent Systems Program University of Pittsburgh  Pittsburgh Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Egbert","sequence":"additional","affiliation":[{"name":"Department of Chemistry University of Manitoba  Winnipeg Manitoba Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary F.","family":"Paine","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences College of Pharmacy and Pharmaceutical Sciences, Washington State University  Spokane WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2993-2085","authenticated-orcid":false,"given":"Richard D.","family":"Boyce","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Pittsburgh  Pittsburgh Pennsylvania USA"},{"name":"Department of Biomedical Informatics University of Pittsburgh  Pittsburgh Pennsylvania USA"},{"name":"Intelligent Systems Program University of Pittsburgh  Pittsburgh Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,12,24]]},"reference":[{"key":"e_1_2_11_2_1","volume-title":"Marijuana and Teens","author":"The American Academy of Child and Adolescent Psychiatry (AACAP)","year":"2023"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.5041\/RMMJ.10386"},{"key":"e_1_2_11_4_1","unstructured":"Key Substance Use and Mental Health Indicators in the United States: Results from the 2021 National Survey on Drug Use and Health (2021)."},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.120.000350"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.05.001"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.121.000734"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.120.000073"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2973"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13710"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1H423"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13505"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0146-y"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-3256"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2018.08.025"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3338"},{"key":"e_1_2_11_17_1","volume-title":"Medical Genetics Summaries [Internet]","author":"Dean L.","year":"2017"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.121.000442"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinane.2018.12.040"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/03602532.2024.2346767"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/2329048X20947896"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16071"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1695786"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199701000-00016"},{"key":"e_1_2_11_25_1","first-page":"235","article-title":"MDMA, Methamphetamine, and CYP2D6 Pharmacogenetics: What Is Clinically Relevant?","volume":"3","author":"Torre R.","year":"2012","journal-title":"Frontiers in Genetics"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241150-00002"},{"key":"e_1_2_11_27_1","unstructured":"205836s009 205837s007 205838s006lbl.pdf [Internet] (2023) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/205836s009 205837s007 205838s006lbl.pdf."},{"key":"e_1_2_11_28_1","unstructured":"020031s067 020710s031.pdf [Internet] (2023) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020031s067 020710s031.pdf."},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.14740\/ijcp386"},{"key":"e_1_2_11_30_1","unstructured":"022334s6lbl.pdf [Internet] (2023) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022334s6lbl.pdf."},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001568"},{"key":"e_1_2_11_32_1","unstructured":"018936s108lbl.pdf [Internet] (2023) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/018936s108lbl.pdf."}],"container-title":["Pharmacology Research &amp; Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.70046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T10:54:44Z","timestamp":1739444084000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/prp2.70046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,24]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1002\/prp2.70046"],"URL":"https:\/\/doi.org\/10.1002\/prp2.70046","archive":["Portico"],"relation":{},"ISSN":["2052-1707","2052-1707"],"issn-type":[{"value":"2052-1707","type":"print"},{"value":"2052-1707","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,24]]},"assertion":[{"value":"2024-07-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70046"}}